Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03093116
Title	A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Acronym	TRIDENT-1
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Turning Point Therapeutics, Inc.
Indications	Advanced Solid Tumor lung non-small cell carcinoma
Therapies	Repotrectinib
Age Groups:	child \| senior \| adult
Covered Countries	USA \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL \| AUS